A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens

Comparison of one-year costs of Type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany

(2011) S. Pscherer et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis

(2011) Anne-Laure Guillermin et al.   JOURNAL OF MEDICAL ECONOMICS

Assessment of adherence and healthcare costs of insulin device (FlexPen®) versus conventional vial/syringe

(2010) Onur Baser et al.   ADVANCES IN THERAPY

A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs

(2010) S. G. Swinnen et al.   DIABETES CARE

Standards of Medical Care in Diabetes--2011

(2010)   DIABETES CARE

The Role of Basal Insulin and Glucagon-Like Peptide-1 Agonists in the Therapeutic Management of Type 2 Diabetes—A Comprehensive Review

(2010) Satish K. Garg   Diabetes Technology & Therapeutics

Influence of Intensive versus Conventional Glucose Control on Microvascular and Macrovascular Complications in Type 1 and 2 Diabetes Mellitus

(2010) Taina K. Mattila et al.   DRUGS

A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study

(2010) J. Gordon et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Comparing Insulins Detemir and Glargine in Type 2 Diabetes: More Similarities than Differences

(2010) L. Raymond Reynolds   POSTGRADUATE MEDICINE

Comparison of insulin detemir and insulin glargine in a basal—bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, Treat-to-Target noninferiority trial

(2009) Simon Heller et al.   CLINICAL THERAPEUTICS

Global estimates of the prevalence of diabetes for 2010 and 2030

(2009) J.E. Shaw et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes

(2009) Philip Raskin et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Too Much Ado about Instrumental Variable Approach: Is the Cure Worse than the Disease?

(2009) Onur Baser   VALUE IN HEALTH

Economic Costs of Diabetes in the U.S. in 2007

(2008)   DIABETES CARE

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

(2008) J. Rosenstock et al.   DIABETOLOGIA

Stemming the global obesity epidemic: What can we learn from data about social and economic trends?

(2008) Roland Sturm   PUBLIC HEALTH

How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus?

(2008) Jennifer B Marks   Nature clinical practice. Endocrinology & metabolism